Track OPTHEA LIMITED — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

OPTHEA LIMITED UKJ.F · Stock Open OPTHEA LIMITED in new tab

0.005200 EUR
Add to portfolio
P/B
0.43
Beta
1.53
1M 6M YTD 1Y 2Y 5Y Max
Loading chart...
Key Metrics
Book Value0.02
Price to Book0.43
Growth
Revenue Growth-1.00%

DCF Valuation

Tweak assumptions to recompute fair value for OPTHEA LIMITED (UKJ.F)
Currency: EUR
DCF Assumptions
Decimal (e.g., 0.10 = 10%). Range allows declines (−50%) to strong growth (+50%).
Decimal (e.g., 0.30 = 30%).
Decimal (e.g., 0.04 = 4%).
Decimal (e.g., 0.20 = 20%).
Percent number (e.g., 3 = 3%).
Percent number (e.g., 10 = 10%).
Percent number (e.g., 5 = 5%).
DCF Result
Fair Value (DCF)
—
Current Price
—
Upside
—
WACC
—
Terminal PV
—
Σ PV of FCFs
—
Note: historical bars show reported FCF (for context); forward bars show PV of projected FCF; if no per-year data, totals are shown.

OPTHEA LIMITED Logo OPTHEA LIMITED Analysis (UKJ.F)

Australia Health Care Official Website Stock

Is OPTHEA LIMITED a good investment? OPTHEA LIMITED (UKJ.F) is currently trading at 0.005200 EUR.

Investor FAQ

Does OPTHEA LIMITED pay a dividend?

No, it does not currently pay a dividend.

What asset class is OPTHEA LIMITED?

OPTHEA LIMITED is classified as a Stock. You can compare it against 3 other assets in the "Related Symbols" list on this page.

Company Profile

Ceryvyn Therapeutics Limited, a clinical-stage biopharmaceutical company, researches and develops therapeutic products based on targeting vascular endothelial growth factors (VEGF) C, D and R3 in Australia and the United States. The company's pipeline includes Sozinibercept, which is in phase 3 to treat wet age-related macular degeneration (Wet AMD), as well as in phase 2 to treat diabetic macular edema (DME). It serves the biotechnology and healthcare industries. The company was formerly known as Opthea Limited and changed its name to Ceryvyn Therapeutics Limited in July 2026. Ceryvyn Therapeutics Limited was incorporated in 1984 and is headquartered in Melbourne, Australia.

Exchange Ticker
FRA (Germany) UKJ.F
ASX (Australia) OPT.AX
PNK (United States) CKDXF
Trades
No dividend information available for this instrument.
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Fundamentals

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion